Home > Insider Trading > Filing (0000875320-24-000059)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1242825	M Jeffrey Leiden	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Executive Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-02-12	2,009	$419.22	28,291	No	4	S	Direct
Common Stock	Disposition	2024-02-12	647	$420.39	27,644	No	4	S	Direct
Common Stock	Disposition	2024-02-13	737	$419.13	26,907	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	440	Indirect	401(k)

Footnotes

Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71).
Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94).
Open market sales reported on this line occurred at a weighted average price of $419.13 (range $419.00 to $419.37).